Physician profile
Mei Jiang
NPI 1124386016
$3,931.81
in general payments reported to CMS, 2019-2025
28 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $315 · 2023: $898 · 2024: $1,300 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $979.06 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $416.89 | 2023-2025 | Daybue |
| Jazz Pharmaceuticals INC. | $274.10 | 2023-2025 | |
| Ns Pharma, INC. | $230.70 | 2023-2025 | Viltepso |
| Sarepta Therapeutics, INC. | $229.26 | 2022-2025 | Elevidys |
| Catalyst Pharmaceuticals, INC. | $223.05 | 2024-2025 | |
| Neurelis, INC. | $183.76 | 2022-2025 | Valtoco |
| Biogen, INC. | $179.57 | 2023-2025 | Spinraza |
| Sk Life Science, INC. | $155.80 | 2024 | |
| Ptc Therapeutics, INC. | $149.69 | 2022-2024 | Emflaza |
| Alexion Pharmaceuticals, INC. | $130.20 | 2023-2025 | Koselugo |
| Genentech USA, INC. | $113.81 | 2023-2025 | Evrysdi |
| Livanova USA, INC. | $86.70 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Biocodex, INC. | $83.54 | 2023-2025 | Diacomit |
| Itf Therapeutics LLC | $73.46 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $72.90 | 2025 | |
| Ironshore Pharmaceuticals INC. | $52.51 | 2024 | |
| Aquestive Therapeutics, INC. | $44.88 | 2024 | |
| Aucta Pharmaceuticals, INC. | $39.46 | 2024-2025 | Motpoly Xr |
| Pyros Pharmaceuticals, INC. | $38.64 | 2024 | Vigpoder |
| Immedica Pharma US, INC. | $37.38 | 2023 | |
| Springworks Therapeutics, INC. | $26.49 | 2025 | Gomekli |
| Nobelpharma America, LLC | $21.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.90 | 2025 | |
| Cranial Technologies, INC | $18.62 | 2025 | Doc Band |
| Biomarin Pharmaceutical INC. | $17.96 | 2024 | Brineura |
| Amneal Pharmaceuticals LLC | $17.60 | 2023 | Lyvispah |
| Avadel Cns Pharmaceuticals, LLC | $15.79 | 2025 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.